Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744789 | 0.86 | RXRA (0.68) | MAPTKDM4ERXRAGRIK1GRIA1 | |
| SCHEMBL1607173 | 0.85 | LMNA (0.62) | KDM4ELMNACYP2C8RXRANPC1 | |
| SCHEMBL29651459 | 0.85 | LMNA (0.62) | KDM4ELMNACYP2C8RXRANPC1 | |
| SCHEMBL2744549 | 0.85 | RXRA (0.68) | LMNARXRAGRIK1GRIA1GRIA2 | |
| SCHEMBL2744656 | 0.83 | ABL1 (0.51) | RXRAGRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL2744548 | 0.83 | CA1 (0.59) | KDM4ELMNACYP2C8RXRAGRIK1 | |
| SCHEMBL26464789 | 0.81 | GRIK1 (0.55) | MAPTRXRAGRIK1GRIA1GRIA2 | |
| SCHEMBL30765461 | 0.81 | AKR1C3 (0.64) | KDM4ELMNACYP2C8RXRARAB9A | |
| SCHEMBL4254012 | 0.81 | STIM1 (0.62) | KDM4ELMNANPC1MITFRAB9A | |
| SCHEMBL2744081 | 0.81 | GRIK1 (0.56) | MAPTKDM4EGRIK1GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | claimed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | claimed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | claimed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | BUONAMICI SILVIA (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | DORSCH MARION (US) | 2014-07-17 | — | — | US | disclosed |
| US-8778927-B2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| WO-2010037715-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2010-04-08 | — | — | WO | disclosed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | MTOR, ULK1, HRAS | MAPT 2974/4885KDM4E 1283/4885LMNA 3318/4885 |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | MAPT 2530/4885KDM4E 2329/4885LMNA 2318/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | MAPT 4534/4885KDM4E 1039/4885LMNA 4269/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4520/4885KDM4E 1129/4885LMNA 4488/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4520/4885KDM4E 1129/4885LMNA 4488/4885 |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | MAPT 3710/4885KDM4E 1460/4885LMNA 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.